ArticleBiochemistry and biophysics reports2025
Ganoderma lucidum polysaccharide attenuates retinal ischemia-reperfusion injury by regulating microglial M1/M2 polarization, suppressing neuroinflammation and inhibiting JAK2/STAT3 pathway.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanism of Ganoderma lucidum polysaccharides in the mangement of diabetes and its complications.Frontiers in pharmacology · 2026Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal ischemia-reperfusion (RIR) injury is implicated in the pathogenesis of numerous retinal degenerative disorders, resulting in visual impairment or even blindness in millions of individuals worldwide. In recent years, targeting the suppression of microglia-mediated neuroinflammation has emerged as a principal therapeutic strategy for RIR. Ganoderma lucidum polysaccharide (GLP), a pivotal bioactive extract of Ganoderma lucidum, has been demonstrated to possess efficacious anti-neuroinflammatory properties, while the precise impact of it on RIR injury remains incompletely elucidated. In this study, the RIR model was induced in Sprague-Dawley rats by elevating the intraocular pressure to 80 mmHg for 60 min. Our findings revealed that GLP significantly alleviated inflammatory processes by impeding the secretion of pro-inflammatory cytokines while facilitating that of anti-inflammatory cytokines. Moreover, the administration of GLP also promoted the polarization of microglia from the M1 phenotype to the M2 phenotype. Further investigation of the treatment mechanism indicated that the regulatory effects of GLP were presumably mediated by the inhibition of the JAK2/STAT3 signaling pathway. To summarize, we provided a novel insight into the mechanisms by which GLP ameliorated RIR injury, thereby indicating that it could be identified as a promising candidate for the management of RIR-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.